ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد

Hydrochlorothiazide: Drug information

Hydrochlorothiazide: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Hydrochlorothiazide: Patient drug information" and "Hydrochlorothiazide: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Inzirqo
Brand Names: Canada
  • APO-Hydro [DSC];
  • APO-Hydrochlorothiazide;
  • MINT-Hydrochlorothiazide;
  • PMS-Hydrochlorothiazide;
  • TEVA-Hydrochlorothiazide
Pharmacologic Category
  • Antihypertensive;
  • Diuretic, Thiazide
Dosing: Adult
Calcium nephrolithiasis, prevention

Calcium nephrolithiasis, prevention (off-label use):

Oral: Initial: 25 mg once daily; titrate based on tolerance and urinary calcium levels to usual effective dose of 50 to 100 mg/day in 1 to 2 divided doses (Ref).

Diabetes insipidus, nephrogenic

Diabetes insipidus, nephrogenic (off-label use):

Note: Consider for use in addition to a low-solute diet to help reduce polyuria (Ref).

Oral: 25 mg once or twice daily (Ref).

Edema or general volume overload

Edema or general volume overload (adjunctive to loop diuretic):

Note : Optimize loop diuretic therapy before adding hydrochlorothiazide; combination diuretic therapy is typically for short-term use to restore euvolemia in patients already taking high-dose loop diuretic therapy who are resistant (eg, furosemide total daily dose of 160 to 320 mg/day IV or the oral equivalent). Combination diuretic therapy can cause severe electrolyte depletion (eg, potassium, magnesium, sodium); prior to and during therapy, electrolytes should be monitored and appropriately managed (Ref).

Oral: Initial: 25 to 50 mg once or twice daily; may increase dose as needed based on response and tolerability up to a maximum of 200 mg/day; may be administered in combination with or shortly before the scheduled loop diuretic. Assess volume status frequently (eg, daily or at least every 2 to 3 days) to determine effectiveness and avoid over-diuresis. Continue until euvolemia is restored, although some patients may require maintenance therapy (Ref).

Hypertension, chronic

Hypertension, chronic (alternative agent):

Note: When a thiazide diuretic is chosen, chlorthalidone or indapamide is preferred (Ref). For patients who warrant combination therapy (blood pressure ≥20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use in combination with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, dihydropyridine calcium channel blocker) (Ref). However, some experts prefer regimens that do not include thiazide diuretics for combination therapy (Ref).

Oral: Initial: 12.5 to 25 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose, as needed, up to 50 mg once daily (Ref); some experts do not recommend doses higher than 25 mg/day because of greater adverse effects without additional antihypertensive effect; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

CrCl ≥10 mL/minute: No dosage adjustment necessary. The diuretic effect is diminished with CrCl <30 mL/minute, but small, short-term studies suggest hypertensive benefit may be preserved (Ref). Switching to a loop diuretic may be considered if BP is no longer controlled or if management of fluid overload is required (Ref).

CrCl <10 mL/minute: Use not recommended due to lack of efficacy (Ref).

Hemodialysis, intermittent (thrice weekly): Not dialyzable (Ref); use not recommended due to lack of efficacy (Ref).

Peritoneal dialysis: Use not recommended due to lack of efficacy (Ref).

CRRT: In general, use not recommended; fluid management can be more effectively managed using CRRT ultrafiltration (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): In general, use not recommended; fluid management can be more effectively managed using PIRRT ultrafiltration (Ref).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling. However, use with caution and monitor for precipitation of hepatic coma.

Dosing: Older Adult

Oral: Initial: 12.5 mg once daily; titrate as necessary in increments of 12.5 mg. Minimal increase in response and more electrolyte disturbances are seen with doses >50 mg daily.

Dosing: Pediatric

(For additional information see "Hydrochlorothiazide: Pediatric drug information")

Dosage guidance:

Dosing: Oral suspension may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 5 mg/mL); use extra precaution to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg as appropriate (ie, not in mL or number of tablets).

Bronchopulmonary dysplasia

Bronchopulmonary dysplasia (BPD): Limited data available; efficacy results variable. Note: Although the benefits of diuretic therapy in management of BPD are variable (eg, optimal duration of therapy, impact on pulmonary endpoints), diuretics continue to be used in clinical practice (Ref).

Infants: Oral: 3 to 4 mg/kg/day in 2 divided doses (Ref).

Diabetes insipidus, central

Diabetes insipidus, central: Very limited data available: Infants and Children <3 years: Oral: 1 to 2 mg/kg/day. Dosing based on retrospective descriptive analysis (n=13, age range: 0.5 to 27 months) (Ref).

Edema

Edema (diuresis):

Infants <6 months: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; some infants may require 3 mg/kg/day in 2 divided doses; maximum daily dose: 37.5 mg/day (Ref).

Infants ≥6 months and Children <2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 37.5 mg/day (Ref).

Children ≥2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 100 mg/day (Ref).

Adolescents: Limited data available: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses (Ref). Note: Maximum adult daily dose recommended for heart failure-related edema: 200 mg/day (Ref).

Hypertension

Hypertension:

Infants <6 months: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; some infants may require 3 mg/kg/day in 2 divided doses; maximum daily dose: 37.5 mg/day (Ref).

Infants ≥6 months and Children <2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 37.5 mg/day (Ref).

Children ≥2 years: Oral: 1 to 2 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 100 mg/day (Ref); a lower maximum dose of 37.5 mg/day has been suggested by recent guidelines (Ref).

Adolescents: Limited data available: Oral: Initial: 1 mg/kg/day once daily; may increase to maximum daily dose: 3 mg/kg/day or 50 mg/day, whichever is lower (Ref).

Hypercalciuria

Hypercalciuria: Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mg/kg/day in 1 to 2 divided doses; lower initial doses of 0.5 mg/kg/day has been reported in infants and children; titrate until goal urinary calcium excretion goals reached and symptoms resolve; treatment usually continued for 1 year; usual adult dose: 25 to 100 mg/day (Ref).

Nephrogenic diabetes insipidus, congenital

Nephrogenic diabetes insipidus, congenital: Limited data available: Infants, Children, and Adolescents: Oral: Usual dosage range: 1 to 3 mg/kg/day in combination with amiloride. Dosing based on a retrospective descriptive analysis (n=30, age range: 1 month to 40 years), and a retrospective analysis (n=10, median age at diagnosis: 1.6 years [age range: 0.16 to 6.33 years]), and a pediatric case series (n=4) in patients receiving hydrochlorothiazide in combination with amiloride (Ref). In adults, usual dose is 25 mg once or twice daily (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Altered kidney function: Infants, Children, and Adolescents:

There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Ref):

GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.

GFR <30 mL/minute/1.73 m2: Use not recommended; use is contraindicated with anuria.

Hemodialysis, intermittent: Not dialyzable (Ref); there are no dosage adjustments provided in the manufacturer's labeling; use not recommended (Ref).

Peritoneal dialysis: There are no dosage adjustments provided in the manufacturer's labeling; use not recommended (Ref).

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution in patients with liver impairment and monitor for precipitation of hepatic coma.

Adverse Reactions (Significant): Considerations
Dermatologic toxicity

Skin photosensitivity may occur with hydrochlorothiazide. Cumulative use may increase the risk for squamous cell carcinoma (SCC) of skin (lip) and basal cell carcinoma (BCC) of skin (Ref).

Mechanism: Skin photosensitivity: Non-dose-related; idiosyncratic. Diuretics reduce the minimum UV radiation needed to produce a sunburn-like response, increasing the risk of phototoxicity and potentially photocarcinogenesis (Ref). SCC and BCC: Dose- and time-related (Ref); risk may be mediated through skin photosensitivity (Ref).

Onset: SCC/BCC: Delayed (Ref)

Risk factors:

SCC/BCC:

• Cumulative use (ie, ≥5 years) (Ref)

Electrolyte disturbances

Reversible hypokalemia, hypomagnesemia, hypercalcemia, and hyponatremia may occur with hydrochlorothiazide and may increase the risk of arrhythmias. Development of electrolyte disturbances may be minimized when used in combination with other electrolyte-sparing antihypertensives (eg, angiotensin-converting enzyme, angiotensin receptor blockers, or aldosterone inhibitors) (Ref).

Mechanism: Dose-related; related to the pharmacologic action. Thiazide diuretics block the NaCl cotransporter in the distal convoluted tubule, leading to decreased reabsorption of sodium and chloride and increased delivery of sodium to the collecting duct, which leads to increased potassium wasting. Diluting capacity of the kidney is also impaired, leading to decreased magnesium and increased calcium concentrations (Ref).

Onset: Varied; hypokalemia generally occurs within 2 weeks of initiation (Ref). Hyponatremia onset may range from 2 weeks to 10 years after treatment initiation (Ref).

Risk factors:

• High doses (>25 mg/day) (Ref) or concurrent loop diuretic therapy (Ref)

• Hypokalemia: GI losses (eg, vomiting, diarrhea) (Ref)

• Hypomagnesemia: Heart failure, poor magnesium intake, high alcohol intake (Ref)

• Hyponatremia: Increased water intake (Ref); older patients, females (Ref)

• Hypercalcemia: Older patients, females (Ref)

Gout

Hydrochlorothiazide may cause hyperuricemia and precipitate gout or gouty arthritis in susceptible individuals (Ref).

Mechanism: Dose- and time-related; related to the pharmacologic action. Diuretics increase reabsorption of uric acid in the proximal tubule, reducing urinary excretion, increasing the risk of hyperuricemia and gout (Ref). Volume contraction with use of diuretics may also contribute (Ref).

Onset: Rapid; hyperuricemia and gout generally occur within the first few days of treatment initiation (Ref) but may occur up to one year after treatment initiation (Ref).

Risk factors:

• High doses (Ref)

• Increased duration of therapy (Ref)

• Personal or family history of gout (Ref)

Hypersensitivity reactions (immediate and delayed)

Hypersensitivity reactions, both immediate and delayed, have been reported (Ref). Delayed hypersensitivity reactions range from maculopapular skin rash to severe cutaneous adverse reactions, including acute generalized exanthematous pustulosis (Ref). Other hypersensitivity reactions include interstitial nephritis and interstitial pneumonitis (Ref). Additionally, hydrochlorothiazide has been associated with noncardiogenic pulmonary edema (Ref).

Mechanism: Immediate hypersensitivity reactions: Non-dose-related; immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) (Ref). Delayed hypersensitivity reactions: Non-dose-related; immunologic (ie, involving a T-cell mediated drug-specific immune response) (Ref). Noncardiogenic pulmonary edema: Unknown; various proposed mechanisms including immunologic (Ref), idiosyncratic (Ref), and mast cell or complement activation (Ref).

Onset: Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (Ref). Delayed hypersensitivity reactions: Varied; typically occur days to 6 weeks after drug exposure, but may occur more rapidly (usually within 1 to 4 days) upon reexposure (Ref). Noncardiogenic pulmonary edema: Rapid; occurs within 10 to 150 minutes (Ref); upon rechallenge, symptoms develop more rapidly and are often severe (Ref).

Risk factors:

• Cross-reactivity: Limited published information regarding possible cross-reactivity between hydrochlorothiazide and other sulfonamides (Ref). Cross-reactivity due to antibody production (anaphylaxis) is unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides (Ref). Cross-reactivity among thiazide diuretics is unknown.

Ocular Effects

Sulfa derivatives, such as hydrochlorothiazide, may cause acute transient myopia and acute angle-closure glaucoma which is generally reversible (Ref).

Mechanism: Non-dose-related; idiosyncratic (ie, suggested to involve ciliochoroidal effusion and anterior rotation of the ciliary body, leading to myopic shift and angle closure) (Ref). Hyponatremia may also play a role (Ref).

Onset: Varied; reported to occur between 2 days and 7 years after initiation (Ref).

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Hypotension, vasculitis

Dermatologic: Alopecia, skin rash, toxic epidermal necrolysis, urticaria

Endocrine & metabolic: Hypomagnesemia

Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, gastric irritation, nausea, vomiting

Genitourinary: Glycosuria

Hematologic & oncologic: Aplastic anemia, thrombocytopenia

Hepatic: Intrahepatic cholestatic jaundice

Hypersensitivity: Anaphylaxis

Nervous system: Asthenia, dizziness, headache, paresthesia, restlessness, vertigo

Neuromuscular & skeletal: Muscle spasm

Ophthalmic: Blurred vision, xanthopsia

Renal: Decreased urinary calcium excretion

Miscellaneous: Fever

Postmarketing:

Dermatologic: Acute generalized exanthematous pustulosis (Ref), basal cell carcinoma of skin (Ref), malignant neoplasm of lip (Ref), psoriasis (Ref), skin photosensitivity (Ref), squamous cell carcinoma of skin (Ref), Stevens-Johnson syndrome (Ref)

Endocrine & metabolic: Hypercalcemia (Ref), hyperglycemia (Ref), hyperuricemia (Ref), hypochloremic alkalosis (Ref), hypokalemia (Ref), hyponatremia (Ref)

Gastrointestinal: Pancreatitis (Ref), sialadenitis (Ref)

Genitourinary: Erectile dysfunction (Ref)

Hematologic & oncologic: Agranulocytosis (Ref), hemolytic anemia (Ref), leukopenia (Ref), methemoglobinemia (Ref), purpuric disease (Ref)

Hepatic: Cholestatic hepatitis (Ref), hepatotoxicity (including cholangitis, increased serum alkaline phosphatase, increased serum transaminases, intrahepatic cholestasis) (Ref)

Hypersensitivity: Angioedema (Ref), hypersensitivity angiitis (Ref)

Neuromuscular & skeletal: Systemic lupus erythematosus (Ref)

Ophthalmic: Acute angle-closure glaucoma (Ref), myopia (Ref)

Renal: Interstitial nephritis (Ref)

Respiratory: Interstitial pneumonitis (Ref), noncardiogenic pulmonary edema (Ref)

Contraindications

Hypersensitivity to hydrochlorothiazide, any component of the formulation, or sulfonamide-derived drugs; anuria

Note: Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged.

Canadian labeling: Additional contraindications (not in US labeling): Increasing azotemia and oliguria during treatment of severe progressive renal disease; breast-feeding

Warnings/Precautions

Concerns related to adverse effects:

• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO2NH2). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.

Disease-related concerns:

• Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).

• Ascites due to cirrhosis: Use with extreme caution or avoid hydrochlorothiazide in the management of ascites due to cirrhosis; may lead to rapid development of hyponatremia when used in combination with spironolactone and furosemide (AASLD [Runyon 2012]).

• Bariatric surgery: Dehydration: Avoid diuretics in the immediate postoperative period after bariatric surgery; electrolyte disturbances and dehydration may occur. Diuretics may be resumed, if indicated, once oral fluid intake goals are met (Ziegler 2009).

• Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.

• Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in progressive or severe liver disease, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy/coma.

• Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported.

• Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use; should be discontinued prior to testing for parathyroid function.

• Renal impairment: Cumulative effects may develop, including azotemia, in patients with impaired renal function. Avoid in severe renal disease (ineffective).

• Systemic lupus erythematosus (SLE): May cause SLE exacerbation or activation.

Special populations:

• Surgical patients: If given the morning of surgery, hydrochlorothiazide may render the patient volume depleted and blood pressure may be labile during general anesthesia.

Dosage form specific issues:

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 12.5 mg

Suspension Reconstituted, Oral:

Inzirqo: 10 mg/mL (80 mL) [contains propylene glycol; caramel-mint flavor]

Tablet, Oral:

Generic: 12.5 mg, 25 mg, 50 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Capsules (hydroCHLOROthiazide Oral)

12.5 mg (per each): $0.42 - $0.43

Suspension (reconstituted) (Inzirqo Oral)

10 mg/mL (per mL): $5.71

Tablets (hydroCHLOROthiazide Oral)

12.5 mg (per each): $0.17 - $0.82

25 mg (per each): $0.08

50 mg (per each): $0.13 - $0.16

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Generic: 12.5 mg, 25 mg, 50 mg, 100 mg [DSC]

Administration: Adult

Oral: May administer with or without food; administer early in day to avoid nocturia. Take the last dose of multiple doses no later than 6 PM unless instructed otherwise. Shake oral suspension well prior to use. Administer with an accurate measuring device (eg, calibrated oral syringe); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur).

Administration: Pediatric

Oral: May administer with or without food; administer early in day to avoid nocturia; if multiple daily dosing, the last dose should not be administered later than 6 PM unless instructed otherwise.

Oral suspension (commercially available): Shake well before use. Administer with an accurate measuring device (eg, calibrated oral syringe); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur).

Use: Labeled Indications

Edema or general volume overload: Treatment of edema due to heart failure, various forms of renal dysfunction (eg, nephrotic syndrome, acute glomerulosclerosis, chronic renal failure), or corticosteroid or estrogen therapy. Note: Loop diuretics are typically favored, but hydrochlorothiazide may be used as an adjunctive agent for refractory edema (Brater 2011).

Hypertension, chronic: Management of mild to moderate hypertension.

Use: Off-Label: Adult

Calcium nephrolithiasis, prevention; Diabetes insipidus, nephrogenic

Medication Safety Issues
Sound-alike/look-alike issues:

HydroCHLOROthiazide may be confused with hydrALAZINE, hydrocortisone, hydroxychloroquine, hydrOXYzine, Viskazide

International issues:

Esidrex [multiple international markets] may be confused with Lasix brand name for furosemide [US, Canada, and multiple international markets]

Esidrix [Germany] may be confused with Lasix brand name for furosemide [US, Canada, and multiple international markets]

Microzide [Puerto Rico] may be confused with Maxzide brand name for hydrochlorothiazide/triamterene [US, multiple international markets] and Micronase brand name for glyburide [multiple international markets]

Older Adult: High-Risk Medication:

Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).

Hydrochlorothiazide is identified in the Screening Tool of Older Person's Prescriptions (STOPP) criteria as a potentially inappropriate medication in older adults (≥65 years of age) with severe hypokalemia, hyponatremia, hypercalcemia, history of gout, or severe symptomatic aortic stenosis (O’Mahony 2023).

Other safety concerns:

HCTZ is an error-prone abbreviation (mistaken as hydrocortisone, seen as HCT250 mg)

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Agents with Clinically Relevant Anticholinergic Effects: May increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Ajmaline: Sulfonamides may increase adverse/toxic effects of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C: Monitor

Alcohol (Ethyl): May increase orthostatic hypotensive effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Alfuzosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Allopurinol: Thiazide and Thiazide-Like Diuretics may increase hypersensitivity effects of Allopurinol. Risk C: Monitor

Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification

Aminolevulinic Acid (Systemic): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Systemic). Risk X: Avoid

Aminolevulinic Acid (Topical): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Topical). Risk C: Monitor

Amphetamines: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Angiotensin-Converting Enzyme Inhibitors: Thiazide and Thiazide-Like Diuretics may increase hypotensive effects of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may increase nephrotoxic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Antidiabetic Agents: Hyperglycemia-Associated Agents may decrease therapeutic effects of Antidiabetic Agents. Risk C: Monitor

Antidiabetic Agents: Thiazide and Thiazide-Like Diuretics may decrease therapeutic effects of Antidiabetic Agents. Risk C: Monitor

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Arsenic Trioxide: Thiazide and Thiazide-Like Diuretics may increase hypotensive effects of Arsenic Trioxide. Thiazide and Thiazide-Like Diuretics may increase QTc-prolonging effects of Arsenic Trioxide. Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the thiazide and thiazide-like diuretics. Risk D: Consider Therapy Modification

Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Beta2-Agonists: May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Bile Acid Sequestrants: May decrease absorption of Thiazide and Thiazide-Like Diuretics. Management: Separate administration of bile acid sequestrants and oral thiazide diuretics by at least 4 hours. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. Risk D: Consider Therapy Modification

Brigatinib: May decrease antihypertensive effects of Antihypertensive Agents. Brigatinib may increase bradycardic effects of Antihypertensive Agents. Risk C: Monitor

Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid

Calcium Salts: Thiazide and Thiazide-Like Diuretics may increase serum concentration of Calcium Salts. Risk C: Monitor

Cardiac Glycosides: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics. Risk C: Monitor

Corticosteroids (Systemic): May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

CycloPHOSphamide: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of CycloPHOSphamide. Specifically, granulocytopenia may be enhanced. Risk C: Monitor

Desmopressin: Hyponatremia-Associated Agents may increase hyponatremic effects of Desmopressin. Risk C: Monitor

Dexketoprofen: May increase adverse/toxic effects of Sulfonamides. Risk C: Monitor

Dexmethylphenidate: May decrease therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Diacerein: May increase therapeutic effects of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased. Risk C: Monitor

Diazoxide Choline: May increase adverse/toxic effects of Thiazide and Thiazide-Like Diuretics. Specifically, the hyperglycemic and hyperuricemic effects may be increased. Risk C: Monitor

Diazoxide: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of Diazoxide. Risk C: Monitor

Dichlorphenamide: Thiazide and Thiazide-Like Diuretics may increase hypokalemic effects of Dichlorphenamide. Risk C: Monitor

Dofetilide: HydroCHLOROthiazide may increase QTc-prolonging effects of Dofetilide. HydroCHLOROthiazide may increase serum concentration of Dofetilide. Risk X: Avoid

DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor

EPINEPHrine (Systemic): Diuretics may increase arrhythmogenic effects of EPINEPHrine (Systemic). Diuretics may decrease vasopressor effects of EPINEPHrine (Systemic). Risk C: Monitor

Flunarizine: May increase therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Herbal Products with Blood Pressure Increasing Effects: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Iloperidone: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Indoramin: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Ipragliflozin: May increase adverse/toxic effects of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased. Risk C: Monitor

Isocarboxazid: May increase hypotensive effects of Diuretics. Risk X: Avoid

Ivabradine: Thiazide and Thiazide-Like Diuretics may increase arrhythmogenic effects of Ivabradine. Risk C: Monitor

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may increase hypotensive effects of Levodopa-Foslevodopa. Risk C: Monitor

Levosulpiride: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of Levosulpiride. Risk X: Avoid

Licorice: May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Lithium: Thiazide and Thiazide-Like Diuretics may decrease excretion of Lithium. Management: Reduce the lithium dose if coadministered with thiazide or thiazide-like diuretics. Monitor serum lithium levels during coadministration with thiazide and thiazide-like diuretics. Risk D: Consider Therapy Modification

Loop Diuretics: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Lormetazepam: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Mecamylamine: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of Mecamylamine. Management: Consider avoiding the use of mecamylamine and thiazide diuretics. If combined, mecamylamine prescribing information suggests reducing the mecamylamine dose by 50% in order to avoid excessive hypotension. Risk D: Consider Therapy Modification

Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor

Methenamine: Thiazide and Thiazide-Like Diuretics may decrease therapeutic effects of Methenamine. Risk C: Monitor

Methotrexate: HydroCHLOROthiazide may increase nephrotoxic effects of Methotrexate. Risk C: Monitor

Methoxsalen (Systemic): Photosensitizing Agents may increase photosensitizing effects of Methoxsalen (Systemic). Risk C: Monitor

Methylphenidate: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Multivitamins/Fluoride (with ADE): May increase hypercalcemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide and Thiazide-Like Diuretics may increase hypercalcemic effects of Multivitamins/Minerals (with ADEK, Folate, Iron). Risk C: Monitor

Multivitamins/Minerals (with AE, No Iron): Thiazide and Thiazide-Like Diuretics may increase serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, thiazide diuretics may decrease the excretion of calcium, and continued concomitant use can also result in metabolic alkalosis. Risk C: Monitor

Naftopidil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Neuromuscular-Blocking Agents (Nondepolarizing): Thiazide and Thiazide-Like Diuretics may increase neuromuscular-blocking effects of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor

Nicergoline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (Topical): May decrease therapeutic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: May decrease therapeutic effects of Thiazide and Thiazide-Like Diuretics. Thiazide and Thiazide-Like Diuretics may increase nephrotoxic effects of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor

Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification

Opioid Agonists: May increase adverse/toxic effects of Diuretics. Opioid Agonists may decrease therapeutic effects of Diuretics. Risk C: Monitor

Palopegteriparatide: Thiazide and Thiazide-Like Diuretics may increase therapeutic effects of Palopegteriparatide. Thiazide and Thiazide-Like Diuretics may decrease therapeutic effects of Palopegteriparatide. Risk C: Monitor

Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Perazine: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Pholcodine: Blood Pressure Lowering Agents may increase hypotensive effects of Pholcodine. Risk C: Monitor

Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Piperacillin: May increase hypokalemic effects of Diuretics. Risk C: Monitor

Polyethylene Glycol-Electrolyte Solution: Diuretics may increase nephrotoxic effects of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor

Porfimer: Photosensitizing Agents may increase photosensitizing effects of Porfimer. Risk X: Avoid

Prazosin: Antihypertensive Agents may increase hypotensive effects of Prazosin. Risk C: Monitor

Promazine: Thiazide and Thiazide-Like Diuretics may increase QTc-prolonging effects of Promazine. Risk X: Avoid

Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Reboxetine: May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Selective Serotonin Reuptake Inhibitor: May increase hyponatremic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Silodosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Sodium Phosphates: Diuretics may increase nephrotoxic effects of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Risk C: Monitor

Sotagliflozin: HydroCHLOROthiazide may decrease therapeutic effects of Sotagliflozin. Sotagliflozin may decrease serum concentration of HydroCHLOROthiazide. Risk C: Monitor

Terazosin: Antihypertensive Agents may increase hypotensive effects of Terazosin. Risk C: Monitor

Topiramate: Thiazide and Thiazide-Like Diuretics may increase hypokalemic effects of Topiramate. Thiazide and Thiazide-Like Diuretics may increase serum concentration of Topiramate. Risk C: Monitor

Toremifene: Thiazide and Thiazide-Like Diuretics may increase hypercalcemic effects of Toremifene. Risk C: Monitor

Urapidil: Antihypertensive Agents may increase hypotensive effects of Urapidil. Risk C: Monitor

Verteporfin: Photosensitizing Agents may increase photosensitizing effects of Verteporfin. Risk C: Monitor

Vitamin D Analogs: Thiazide and Thiazide-Like Diuretics may increase hypercalcemic effects of Vitamin D Analogs. Risk C: Monitor

Reproductive Considerations

When diuretics are used for the treatment of heart failure in patients planning to become pregnant, adjust dose prior to conception to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]).

Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Hydrochlorothiazide is a second-line agent for the treatment of hypertension in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019; SOGC [Magee 2022]).

Pregnancy Considerations

Hydrochlorothiazide crosses the placenta (Beerman 1980).

Maternal use may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults.

Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke and myocardial infarction (ACOG 2019). Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). Hydrochlorothiazide is a second-line agent for the treatment of hypertension in pregnant patients (ACOG 2019; SOGC [Magee 2022]).

Use of thiazide diuretics during pregnancy may be considered to treat edema due to pathologic causes (as in the nonpregnant patient); monitor.

Heart failure in pregnancy is associated with adverse maternal and fetal outcomes, including premature birth, infants born small-for-gestational-age, increased risk of maternal and fetal death (Bright 2021). Thiazide diuretics may be used for symptom management in pregnant patients with heart failure complicated by pulmonary congestion; closely monitor volume status and adjust dose to minimize risk of placental hypoperfusion (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]).

A case report describes the use of hydrochlorothiazide for the treatment of nephrogenic diabetes insipidus during pregnancy (Gala-Błądzińska 2018).

Breastfeeding Considerations

Hydrochlorothiazide is present in breast milk.

Data related to the presence of hydrochlorothiazide in breast milk are available from one mother taking hydrochlorothiazide 50 mg once daily for 3.5 years. The study was conducted 28 days postpartum; breast milk was sampled prior to and at intervals for ~23 hours after the dose. Trough breast milk concentrations were ~50 ng/mL and the mean breast milk concentration was 80 ng/mL. The highest breast milk concentrations of hydrochlorothiazide occurred between ~4 to 10 hours after the dose. Hydrochlorothiazide was not detected in the infant serum (limit of detection 20 ng/mL) (Miller 1982).

• Using a mean milk concentration of 80 ng/mL, the estimated exposure of hydrochlorothiazide to the breastfeeding infant would be 0.012 mg/kg/day (relative infant dose [RID] 0.6% to 1.2% when compared to an infant therapeutic dose of 1 to 2 mg/kg/day).

• In general, breastfeeding is considered acceptable when the RID is <10% (Anderson 2016; Ito 2000).

Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. Hydrochlorothiazide is considered compatible with breastfeeding (WHO 2002). However, thiazide diuretics have the potential to decrease milk volume and suppress lactation; use should be avoided when possible (ACOG 2019; WHO 2002).

Monitoring Parameters

Blood pressure; fluid intake and output; serum electrolytes; BUN, serum creatinine; skin to assess for photosensitivity and skin cancer; visual acuity, ocular pain.

Mechanism of Action

Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Diuresis: Infants: 2 to 6 hours (Chemtob 1989); Adults: ~2 hours.

Peak effect: ~4 hours.

Duration: Infants: 8 hours (Chemtob 1989); Adults: 6 to 12 hours.

Absorption: Well absorbed; absorption is reduced in patients with CHF.

Distribution: 3.6 to 7.8 L/kg (correlates with dose administered and concentration achieved).

Protein binding: ~40% to 70%.

Metabolism: Not metabolized.

Bioavailability: 65% to 75%.

Half-life elimination: Capsule/tablet: ~6 to 15 hours; oral suspension: ~10 hours.

Time to peak: Capsule/tablet: ~1 to 5 hours; oral suspension: ~1.5 hours, delayed 2 hours when administered after a high-fat, high-calorie meal.

Excretion: Urine (≥61% as unchanged drug).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Hydrochlorothiazide plasma concentration is increased and the half-life is prolonged.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Dichlotride | Esidrex | Monozide;
  • (AR) Argentina: Diural | Diurex | Diuriten | HCT 25 | Klortiazida | Tandiur;
  • (AT) Austria: Hct Lannacher;
  • (AU) Australia: Dithiazide;
  • (BD) Bangladesh: Acuren | Htz;
  • (BG) Bulgaria: Dehydratin Neo | Dehydrazid | Hypodehydra;
  • (BR) Brazil: Clorana | Clorizin | Diureclor | Diurepina | Diuretic | Diuretil | Diurezin | Diurix | Drenol | Farmanguinhos hidroclorotiazida | Furp hidroclorotiazida | Hidrazim | Hidrobio | Hidroclorana | Hidroclorotiazida | Hidrofall | Hidroflux | Hidrogen | Hidrol | Hidrolan | Hidroless | Hidromed | Hidrotiazida | Iquego hidroclorotiazida | Lafepe hidroclorotiazida | Lfm hidroclorotiazida | Lqfex hidroclorotiazida | Mictrin | Neo hidroclor;
  • (CH) Switzerland: Esidrex;
  • (CI) Côte d'Ivoire: Apo hydro;
  • (CL) Chile: Hidroclorotiazida | Hidroronol;
  • (CN) China: Hydrochlorothiazid;
  • (CO) Colombia: Diclotride | Diurizir | Hidroclorotiazida | Hidroclorotiazida mk | Hydrug | Hydruretic | Lonpra;
  • (CR) Costa Rica: Hidroclorotiazida fb;
  • (CZ) Czech Republic: Hydrochlorothiazid | Hydrochlorothiazid tainex | Hydrochlorothiazide aurovitas;
  • (DE) Germany: Diu-melusin | Esidrex | Esidrix | Hct Aaa | Hct Actavis | Hct aiwa | Hct AL | Hct basf | Hct beta | Hct biochemie | Hct CT | Hct Dexcel | HCT Dura | Hct gamma | Hct hexal | Hct Intermuti | Hct Isis | Hct puren | Hct ratiopharm | HCT Sandoz | Hct Stada | HCT Teva | Hctad | Hydrochlorothiazid Dexcel | Hydrochlorothiazide 1a pharma;
  • (DO) Dominican Republic: H pres | Hiclor | Hidro Pres | Hidrocard | Hidroclorotiazida | Hidroclorotiazida feltrex | Hidroclorotiazida lam | Hidroclorotiazide | Hidrotiadol | Hypress | Olina | Tiaretic;
  • (EC) Ecuador: HCT 25 | Hidroclorotiazida;
  • (EE) Estonia: Hypothiazid;
  • (EG) Egypt: Hct georetic | Hydretic | Hydrex | Hydrozide;
  • (ES) Spain: Drine | Esidrex | Hidroclorotiazid Kern Pharma | Hidroclorotiazida apotex | Hidroclorotiazida aristo | Hidroclorotiazida aurovitas | Hidroclorotiazida kern pharma | Hidroclorotiazida Stada | Hidroclorotiazida vir | Hidrosaluretil | Hydrochlorothiazide sandoz;
  • (FI) Finland: Dichlotride | Hct-sal | Hyclosid | Hydresis | Hydrex | Hydrex semi;
  • (FR) France: Esidrex | Hydrochlorothiazide arrow;
  • (GB) United Kingdom: Direma | Hydrosaluric;
  • (GR) Greece: Diuren | Esidrex | Hydrochlorothiazid;
  • (HK) Hong Kong: Apo hydrochlorothiazide | Dichlotride | Hydrochlorothiazid | Hydrozide;
  • (HU) Hungary: Hypothiazid;
  • (ID) Indonesia: Hct | Hydrochlorothiazid;
  • (IE) Ireland: Hydrosaluric;
  • (IL) Israel: Disothiazide | Esidrex;
  • (IN) India: Aquazide | Clothy | Hctzide | Hydrazide | Hydride | Hydronol | Hydrotz | Hyzide | Klorzide | Pedizide | Xenia;
  • (IQ) Iraq: Diuzid | Hydrazidawa | Urozide;
  • (IS) Iceland: Aquazid;
  • (IT) Italy: Esidrex | Idroclorotiazide Aurobindo;
  • (JO) Jordan: Esidrex | Modrex | Monozide;
  • (JP) Japan: Dichlotride | Maschitt | Maschitt showa | Newtolide | Pantemon;
  • (KE) Kenya: Hymet | Hyzide;
  • (KR) Korea, Republic of: Dichlodide | Dichlozid | Ildong hydrochlorothiazide;
  • (KW) Kuwait: Esidrex;
  • (LB) Lebanon: Esidrex;
  • (LT) Lithuania: Apo hydro | Dehydratin Neo | Hypothiazide;
  • (LU) Luxembourg: Dichlotride | Esidrix;
  • (LV) Latvia: Dehydratin Neo | Disalunil | Hypothiazide;
  • (MA) Morocco: Esidrex;
  • (MX) Mexico: Acortiz | Bidrociral | Diclotride | Diziver | Hidroclorotiazida | Naxtrol | Rofucal | Systocal | Top k | Waser;
  • (MY) Malaysia: Apo hydro | Hydrochlorzide | Hydrorazide | Hydrozide;
  • (NG) Nigeria: Emzor hydrochlorothiazide | Esinil | Exus hydrochlorothiazide | Hydrex | Redrex;
  • (NL) Netherlands: Hydrochloorthiazide | Hydrochloorthiazide A | Hydrochloorthiazide Alpharma | Hydrochloorthiazide apotex | Hydrochloorthiazide ratiopharm | Hydrochloorthiazide sandoz | Hydrochloroth;
  • (NO) Norway: Esidrex | Hydrochlorothiazide orion | Hydromed;
  • (PE) Peru: Acuren | Diclotride | Diurace | Hidroclorotia | Hidroclorotiaz | Hidroclorotiazida | Hidrotiazida | Tiazid | Zinoxid;
  • (PH) Philippines: Altiazide | Dichlotride | Diucare | Diuzid | Diuzide | Hydrax | Hytaz | Pharex hydrochlorothiazide | Urilzid;
  • (PK) Pakistan: Diuza | Urozide;
  • (PL) Poland: Disalunil | Hydrochlorothiazid | Hydrochlorothiazide aurovitas | Hydrochlorothiazide orion | Hypothiazide;
  • (PR) Puerto Rico: Esidrix | Hydrochlorothiazid | Hydrodiuril | Microzide | Oretic;
  • (PT) Portugal: Hidroclorotiazida | Hidrosaluteril;
  • (PY) Paraguay: As farmil | Clorfal | Daretic | Diurex | Hidramil | Hidroclorotiazida heisecke | Hidroclorotiazida polimed | Hidroclorotiazida vivele | Micciol | Rifor;
  • (QA) Qatar: Esidrex | HCT Hexal;
  • (RU) Russian Federation: Dichlothiazid | Hydrochlorothiazid | Hydrochlorothiazide sar | Hypothiazide;
  • (SA) Saudi Arabia: Apo hydro | Apo hydrochlorothiazide | Esidrex | Monozide | Pms hydrochlorothiazide;
  • (SE) Sweden: Esidrex | Hydrochlorothiazide bluefish | Hydrochlorothiazide orifarm | Hydrochlorothiazide orion | Hydroklortiazid ebb | Hydroklortiazid evolan;
  • (SG) Singapore: Apo hydro | Di-Ertride | Didralin | Hichlozide | Hydrochlorzide | Hydrozide;
  • (SK) Slovakia: Hydrochlorothiazid | Hydrochlorothiazid leciva;
  • (SR) Suriname: Apo hydro | Apo hydrochlorothiazide | Hydrochloorthiazide | Hydrochloorthiazide actavis | Hydrochloorthiazide apotex | Hydrochloorthiazide aurobindo | Hydrochloorthiazide mylan | Hydrochloorthiazide sandoz;
  • (TH) Thailand: Apo hydro | Cozide | Didralin | Diuret-p | Hctz | Hychlortide | Hychlorzide | Hydozid | Hydril | Hydrochlorothiazid | Hydromed | Hydrozide | Med-hyazide | Thiazide | Urazide;
  • (TN) Tunisia: Esidrex;
  • (TR) Turkey: Esidrex;
  • (TW) Taiwan: Colonraitai | Depress | Dichlortride | Dichlotride | Dicomtride | Dihydrodiazid | Dithiazide | Hybozide | Hychlotozide | Hychlozide | Hydrochlorothiazid | Hydrochorothiazide | Koliside | Lisuzone | Nisidrex | Uresan;
  • (UA) Ukraine: Hydrochlorothiazid | Hydrothiazide | Hypothiazide | Tiurex;
  • (UY) Uruguay: Di Tiaziden | Diclorazida | Ditiazid | Diurotiazida | Esidrex | Hidroclorotiazida | Hidrotiazida | Modiur | Moduron | Tiaziden;
  • (VE) Venezuela, Bolivarian Republic of: Di-Eudrin | Diclotride | Hidroclorotiazida | Hytide;
  • (ZA) South Africa: Gulf hydrochlorothiazide | Hexazide | Ridaq | Urirex;
  • (ZM) Zambia: Hexazide | Hydrex 50;
  • (ZW) Zimbabwe: Staplex | Varidrex
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Abraham MB, Rao S, Price G, Choong CS. Efficacy of hydrochlorothiazide and low renal solute feed in neonatal central diabetes insipidus with transition to oral desmopressin in early infancy. Int J Pediatr Endocrinol. 2014;2014(1):11. [PubMed 25002871]
  3. Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299-308. doi:10.1016/j.jash.2012.07.004 [PubMed 22951101]
  4. Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, Double-Blind, Controlled Trial of Long-Term Diuretic Therapy for Bronchopulmonary Dysplasia. J Pediatr. 1989;115(4):615-620. [PubMed 2677293]
  5. Al Nofal A, Lteif A. Thiazide diuretics in the management of young children with central diabetes insipidus. J Pediatr. 2015;167(3):658-661. [PubMed 26130110]
  6. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020 [PubMed 30575676]
  7. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  8. Aouam K, Ali HB, Youssef M, et al. Lichenoid eruption associated with hydrochlorothiazide and possible cross reactivity to furosemide. Therapie. 2009;64(5):344-347. doi:10.2515/therapie/2009050 [PubMed 20108448]
  9. Arinzon Z, Alexander P, Berner Y. Hydrochlorothiazide induced hepato-cholestatic liver injury. Age Ageing. 2004;33(5):509-510. doi:10.1093/ageing/afh148 [PubMed 15271638]
  10. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. American College of Physicians; 2007:43.
  11. Arrabal-Martín M, González-Torres S, Cano-García MD, et al. Urine calcium and bone mineral density in calcium stone-forming patients treated with alendronate and hydrochlorothiazide. Urol Int. 2016;97(3):292-298. doi:10.1159/000443484 [PubMed 26800461]
  12. ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.
  13. Assaad D, From L, Ricciatti D, Shapero H. Toxic epidermal necrolysis in Stevens--Johnson syndrome. Can Med Assoc J. 1978;118(2):154-156. [PubMed 757383]
  14. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18(9):1096-1105. [PubMed 27338866]
  15. Beermann B, Fåhraeus L, Groschinsky-Grind M, Lindström B. Placental transfer of hydrochlorothiazide. Gynecol Obstet Invest. 1980;11(1):45-48. [PubMed 7390276]
  16. Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2 [PubMed 31020549]
  17. Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther. 1977;22(5, pt 1):499-504. [PubMed 334435]
  18. Bernal C, Patarca R. Hydrochlorothiazide-induced pulmonary edema and associated immunologic changes. Ann Pharmacother. 1999;33(2):172-174. doi:10.1345/aph.18191 [PubMed 10084412]
  19. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. CMAJ. 1991;145(1):28-34. [PubMed 2049694]
  20. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
  21. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi:10.1210/jc.2015-1710 [PubMed 26760044]
  22. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24(7):856-870. [PubMed 15303450]
  23. Brater DC. Update in diuretic therapy: clinical pharmacology. Semin Nephrol. 2011;31(6):483-494. doi:10.1016/j.semnephrol.2011.09.003 [PubMed 22099505]
  24. Brater DC, Ellison DH. Causes and treatment of refractory edema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 26, 2023.
  25. Bright RA, Lima FV, Avila C, Butler J, Stergiopoulos K. Maternal heart failure. J Am Heart Assoc. 2021;10(14):e021019. doi:10.1161/JAHA.121.021019 [PubMed 34259013]
  26. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  27. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol. 2014;66(1):185-196. doi:10.1002/art.38203 [PubMed 24449584]
  28. Caletti MG, Balestracci A, Di Pinto D. Pre- and post-treatment urinary tract findings in children with nephrogenic diabetes insipidus. Pediatr Nephrol. 2014;29(3):487-490. [PubMed 24337364]
  29. Chaabane A, Fadhel NB, Chadli Z, et al. Association of non-immediate drug hypersensitivity with drug exposure: A case control analysis of spontaneous reports from a Tunisian pharmacovigilance database. Eur J Intern Med. 2018;53:40-44. doi:10.1016/j.ejim.2018.01.032 [PubMed 29409745]
  30. Chemtob S, Kaplan BS, Sherbotie JR, et al. Pharmacology of Diuretics in the Newborn. Pediatr Clin North Am. 1989;36(5):1231-1250. [PubMed 2677940]
  31. Chen SH, Karanjia R, Chevrier RL, Marshall DH. Bilateral acute angle closure glaucoma associated with hydrochlorothiazide-induced hyponatraemia. BMJ Case Rep. 2014;2014:bcr2014206690. doi:10.1136/bcr-2014-206690 [PubMed 25477363]
  32. Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. doi:10.1136/bmj.d8190 [PubMed 22240117]
  33. Choi JN, Lee JS, Shin JI. Low-dose thiazide diuretics in children with idiopathic renal hypercalciuria. Acta Paediatr. 2011;100(8):e71-e74. doi:10.1111/j.1651-2227.2011.02191.x [PubMed 21284722]
  34. Chrein MB, Rubin IL. Agranulocytosis secondary to hydrochlorothiazide therapy. Report of a case. JAMA. 1962;181:54-55. doi:10.1001/jama.1962.03050270056014c [PubMed 13879240]
  35. Constandis DD, Schriever HG. Severe lithium-induced diabetes insipidus in a surgical patient treated with hydrochlorothiazide. Am J Surg. 1981;141(6):741-743. [PubMed 7246868]
  36. Copelovitch L. Urolithiasis in Children: Medical Approach. Pediatr Clin North Am. 2012;59(4):881-896. [PubMed 22857835]
  37. Corominas M, Andrés-López B, Lleonart R. Severe adverse drug reactions induced by hydrochlorothiazide: A persistent old problem. Ann Allergy Asthma Immunol. 2016;117(3):334-335. doi:10.1016/j.anai.2016.07.003 [PubMed 27613469]
  38. Curhan GC. Kidney stones in adults: Prevention of recurrent kidney stones. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 5, 2022.
  39. Desai HV, Gandhi K, Sharma M, Jennine M, Singh P, Brogan M. Thiazide-induced severe hypercalcemia: a case report and review of literature. Am J Ther. 2010;17(6):e234-e236. doi:10.1097/MJT.0b013e3181c6c21b [PubMed 20068444]
  40. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich). 2012;14(1):32-37. doi:10.1111/j.1751-7176.2011.00564.x [PubMed 22235821]
  41. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant. 2005;20(2):349-353. doi:10.1093/ndt/gfh650 [PubMed 15615808]
  42. Earley LE, Orloff J. The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin-resistant diabetes insipidus. J Clin Invest. 1962;41(11):1988-1997. doi:10.1172/JCI104657 [PubMed 16695887]
  43. Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
  44. Engelhardt B, Blalock WA, DonLevy S, et al. Effect of Spironolactone-Hydrochlorothiazide on Lung Function in Infants With Chronic Bronchopulmonary Dysplasia. J Pediatrics. 1989;114:619-624. [PubMed 2926575]
  45. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  46. Fadah K, Rivera M, Lingireddy A, Kalas MA, Ghafouri RS, Deoker A. A rare culprit of methemoglobinemia. J Investig Med High Impact Case Rep. 2022;10:23247096221117919. doi:10.1177/23247096221117919 [PubMed 35959982]
  47. Fanaroff AA, Fanaroff JM, eds. Klaus & Fanaroff's Care of the High-Risk Neonate. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.
  48. Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents [published correction appears in Pediatrics. 2017;140(6):e20173035 and Pediatrics. 2018;142(3):e20181739]. Pediatrics. 2017;140(3):e20171904. [PubMed 29192011]
  49. Frassetto LA, Nash E, Morris RC Jr, Sebastian A. Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion. Kidney Int. 2000;58(2):748-752. [PubMed 10916098]
  50. Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-Hispanic whites. Arch Intern Med. 2012;172(16):1246-1251. doi:10.1001/archinternmed.2012.2754 [PubMed 22869299]
  51. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061 [PubMed 26934393]
  52. Gala-Błądzińska A, Mrozek A, Kędzior A, Mazur A, Darmochwał-Kolarz D. Treatment of congenital nephrogenic diabetes insipidus in pregnancy. Ginekol Pol. 2018;89(2):112-113. doi:10.5603/GP.a2018.0019 [PubMed 29512817]
  53. Geanon JD, Perkins TW. Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide. Arch Ophthalmol. 1995;113(10):1231-1232. doi:10.1001/archopht.1995.01100100019012 [PubMed 7575249]
  54. Goetschalckx K, Ceuppens J, Van Mieghem W. Hydrochlorothiazide-associated noncardiogenic pulmonary oedema and shock: a case report and review of the literature. Acta Cardiol. 2007;62(2):215-220. doi:10.2143/AC.62.2.2020246 [PubMed 17536614]
  55. Greenberg A. Diuretic complications. Am J Med Sci. 2000;319(1):10-24. [PubMed 10653441]
  56. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50(8):953-959. [PubMed 9291881]
  57. Handler J. Managing erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich). 2011;13(6):450-454. doi:10.1111/j.1751-7176.2011.00465.x [PubMed 21649845]
  58. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
  59. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001 [PubMed 31526538]
  60. Hydrochlorothiazide [prescribing information]. Fairfield, NJ: Leading Pharma LLC; October 2015.
  61. Hydrochlorothiazide capsules [prescribing information]. Hauppauge, NY: Sciegen Pharmaceuticals Inc; July 2015.
  62. Hydrochlorothiazide tablet [prescribing information]. Congers, NY: Chartwell Rx LLC; July 2023.
  63. Hydrochlorothiazide tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; May 2011.
  64. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  65. Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. Clin Endocrinol (Oxf). 2015;82(6):789-792. doi:10.1111/cen.12592 [PubMed 25138826]
  66. Inzirqo (hydrochlorothiazide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; January 2025.
  67. Irwin RI, Rippe JM, eds. Irwin and Rippe's Intensive Care Medicine. 6th ed. Lippincott Williams & Wilkins; 2008.
  68. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  69. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428. doi:10.1056/NEJMoa0806182 [PubMed 19052124]
  70. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527-1534. doi:10.1016/j.jacc.2010.06.034 [PubMed 21029871]
  71. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother. 2005;39(2):290-301. [PubMed 15644481]
  72. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Chapter 2: lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients. Kidney Int Suppl (2011). 2012;2(5):347-356. doi: 0.1038/kisup.2012.52. [PubMed 25018961]
  73. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003 [PubMed 33637192]
  74. Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. J Allergy Clin Immunol Pract. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034 [PubMed 31495421]
  75. Kirchlechner V, Koller DY, Seidl R, et al. Treatment of Nephrogenic Diabetes Insipidus With Hydrochlorothiazide and Amiloride. Arch Dis Child. 1999;80(6):548-552. [PubMed 10332005]
  76. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995;26(3):394-400. doi:10.1097/00005344-199509000-00008 [PubMed 8583780]
  77. Knowles SR, Wong GA, Rahim SA, Binkley K, Phillips EJ, Shear NH. Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction. Pharmacotherapy. 2005;25(9):1258-1265. doi:10.1592/phco.2005.25.9.1258 [PubMed 16164399]
  78. Kramer HJ, Townsend RR, Griffin K, et al. KDOQI US commentary on the 2017 ACC/AHA hypertension guideline. Am J Kidney Dis. 2019;73(4):437-458. doi: 10.1053/j.ajkd.2019.01.007 [PubMed 30905361]
  79. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand. 1984;215(4):383-389. [PubMed 6375276]
  80. Leung AA, Wright A, Pazo V, Karson A, Bates DW. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011;124(11):1064-1072. doi:10.1016/j.amjmed.2011.06.031 [PubMed 22017784]
  81. Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002 [PubMed 35577426]
  82. Magil AB, Ballon HS, Cameron EC, Rae A. Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases. Am J Med. 1980;69(6):939-943. doi:10.1016/s0002-9343(80)80023-4 [PubMed 7446559]
  83. Malézieux E, Meunier L, Rivière B, Larrey D. Hydrochlorothiazide-induced hepatotoxicity: a rare case of DILI. Clin Res Hepatol Gastroenterol. 2021;45(5):101599. doi:10.1016/j.clinre.2020.101599 [PubMed 33676268]
  84. Mann JFE, Flack JM. Hypertension in adults: Initial drug therapy. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 7, 2023.
  85. McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1):121-129. doi:10.1002/art.33315 [PubMed 22031222]
  86. McDonald E, Freedman DM, Alexander BH, et al. Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1539-1545. doi:10.1158/1055-9965.EPI-14-0251 [PubMed 24812037]
  87. Meinardi JR, Donders SH. Nephrogenic diabetes insipidus in a lethargic lithium-treated patient. Neth J Med. 1997;50(3):105-109. [PubMed 9121593]
  88. Microzide capsules (hydrochlorothiazide) [prescribing information]. Madison, NJ: Allergan USA, Inc; August 2020.
  89. Microzide capsules (hydrochlorothiazide) [prescribing information]. Morristown, NJ: Watson Pharma Inc; February 2011.
  90. Miller ME, Cohn RD, Burghart PH. Hydrochlorothiazide disposition in a mother and her breast-fed infant. J Pediatr. 1982;101(5):789-791. doi:10.1016/s0022-3476(82)80323-5 [PubMed 7131161]
  91. Mineo MC, Cheng EY. Severe allergic reaction to hydrochlorothiazide mimicking septic shock. Pharmacotherapy. 2009;29(3):357-361. doi:10.1592/phco.29.3.357 [PubMed 19249954]
  92. Naseri M, Sadeghi R. Role of high-dose hydrochlorothiazide in idiopathic hypercalciuric urolithiasis of childhood. Iran J Kidney Dis. 2011;5(3):162-168. [PubMed 21525575]
  93. National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011. National Institutes of Health. http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf. Accessed June 2012.
  94. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004;114(2)(suppl):555-576. [PubMed 15286277]
  95. National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014.
  96. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline, No. 133. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.
  97. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023-00777-y [PubMed 37256475]
  98. Ojji DB, Mayosi B, Francis V, et al; CREOLE Study Investigators. Comparison of dual therapies for lowering blood pressure in black Africans. N Engl J Med. 2019;380(25):2429-2439. doi:10.1056/NEJMoa1901113 [PubMed 30883050]
  99. Okafor KC, Griffin C, Ngole PM. Hydrochlorothiazide-induced thrombocytopenic purpura. Drug Intell Clin Pharm. 1986;20(1):60-61. doi:10.1177/106002808602000110 [PubMed 3943458]
  100. Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol. 2011;31(6):542-552. doi:10.1016/j.semnephrol.2011.09.009 [PubMed 22099511]
  101. Pearle MS, Goldfarb DS, Assimos DG, et al; American Urological Association. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324. [PubMed 24857648]
  102. Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681.e9. doi:10.1016/j.jaad.2017.11.042 [PubMed 29217346]
  103. Pela I, Bigozzi M, Bianchi B. Profound hypokalemia and hypochloremic metabolic alkalosis during thiazide therapy in a child with Pendred syndrome. Clin Nephrol. 2008;69(6):450-453. doi:10.5414/cnp69450 [PubMed 18538122]
  104. Pétavy-Catala C, Martin L, Fontès V, Lorette G, Vaillant L. Hydrochlorothiazide-induced acute generalized exanthematous pustulosis. Acta Derm Venereol. 2001;81(3):209. doi:10.1080/000155501750376348 [PubMed 11558881]
  105. pms-Hydrochlorothiazide (hydrochlorothiazide) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; January 2020.
  106. Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322-331. doi:10.1111/joim.12629 [PubMed 28480532]
  107. Raja R, Kavita F, Amreek F, Shah A, Sayeed KA, Sehar A. Hyperuricemia associated with thiazide diuretics in hypertensive adults. Cureus. 2019;11(8):e5457. doi:10.7759/cureus.5457 [PubMed 31641556]
  108. Reap LE, Rodd C, Larios J, Marshall M. Hydrochlorothiazide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo. BMJ Case Rep. 2019;12(2):e223528. doi:10.1136/bcr-2017-223528 [PubMed 30755424]
  109. Refer to the manufacturer's labeling.
  110. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340 [PubMed 30165544]
  111. Roh YR, Woo SJ, Park KH. Acute-onset bilateral myopia and ciliochoroidal effusion induced by hydrochlorothiazide. Korean J Ophthalmol. 2011;25(3):214-217. doi:10.3341/kjo.2011.25.3.214 [PubMed 21655050]
  112. Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002 [PubMed 25840695]
  113. Rosenthal A, Herrmann J. Hydrochlorothiazide-induced photosensitivity in a psoriasis patient following exposure to narrow-band ultraviolet B excimer therapy. Photodermatol Photoimmunol Photomed. 2019;35(5):369-371. doi:10.1111/phpp.12471 [PubMed 31006143]
  114. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014;19(1):5-13. doi:10.1177/1074248413497257 [PubMed 24243991]
  115. Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 6, 2015. [PubMed 23463403]
  116. Ruscin JM, Page RL 2nd, Scott J. Hydrochlorothiazide-induced angioedema in a patient allergic to sulfonamide antibiotics: evidence from a case report and a review of the literature. Am J Geriatr Pharmacother. 2006;4(4):325-329. doi:10.1016/j.amjopharm.2006.12.002 [PubMed 17296538]
  117. Santos-Victoriano M, Brouhard BH, Cunningham RJ 3rd. Renal stone disease in children. Clin Pediatr (Phila). 1998;37(10):583-599. [PubMed 9793728]
  118. Sardar GK, Eilbert WP. Severe hyponatremia associated with thiazide diuretic use. J Emerg Med. 2015;48(3):305-309. doi:10.1016/j.jemermed.2014.09.054 [PubMed 25499401]
  119. Schell E, Pathman J, Pescatore R, Bianchi PW. A case of thiazide-induced hypokalemic paralysis. Clin Pract Cases Emerg Med. 2019;3(3):211-214. doi:10.5811/cpcem.2019.3.42062 [PubMed 31403094]
  120. Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol. 1982;128(5):903-907. doi:10.1016/s0022-5347(17)53269-3 [PubMed 7176047]
  121. Shah P, Chillag S. Leukocytoclastic vasculitis due to hydrochlorthiazide. J S C Med Assoc. 2007;103(7):194-196. [PubMed 18333584]
  122. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  123. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM. Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia. Transfusion. 1988;28(1):70-72. doi:10.1046/j.1537-2995.1988.28188127959.x [PubMed 3341072]
  124. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639-643. doi:10.1111/j.1751-7176.2011.00512.x [PubMed 21896142]
  125. Sinha AD, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. Clin J Am Soc Nephrol. 2019;14(5):757-764. doi:10.2215/CJN.04330418 [PubMed 30425103]
  126. Sinha AD, Agarwal R. Thiazides are useful agents in CKD. J Am Soc Hypertens. 2016;10(4):288-9. doi:10.1016/j.jash.2016.02.006 [PubMed 26987648]
  127. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am. 2004;24(3):477-490. [PubMed 15242722]
  128. Slaughter JL, Stenger MR, Reagan PB. Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. Pediatrics. 2013;131(4):716-723. [PubMed 23478874]
  129. Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. Published online October 5, 2021. doi:10.1111/bcp.15060 [PubMed 34611920]
  130. Sosenko T, Pasula S, Brahmamdam R, Girnita D. When chest pain reveals more: a case of hydrochlorothiazide-induced systemic lupus erythematosus. Am J Case Rep. 2019;20:26-30. doi:10.12659/AJCR.911380 [PubMed 30613100]
  131. Spera M, Thelin C, Gandolfi A, et al. Clinical case of the month: a 35 year old woman with abdominal pain. J La State Med Soc. 2016;168(3):115-119. [PubMed 27389384]
  132. Sullivan TJ. Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. JAMA. 1991;265(1):120-121. doi:10.1001/jama.265.1.120 [PubMed 1984112]
  133. Taglietti F, Del Nonno F, Baiocchini A, et al. Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report. J Med Case Rep. 2010;4:332. doi:10.1186/1752-1947-4-332 [PubMed 20964809]
  134. Thomopoulos F, Nikitakis NG, Daskalopoulos A, Piperi E, Kolomvos N, Sklavounou A. Chronic sclerosing sialadenitis of the sublingual gland: case report and literature review. Stomatological Dis Sci. 2018;2:8. doi:10.20517/2573-0002.2017.22
  135. Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51(2):57-62. [PubMed 15373844]
  136. Traversa M, Collini A, Villois P, Elia F, Verhovez A, Aprà F. When a diuretic causes pulmonary oedema. Eur J Case Rep Intern Med. 2018;5(6):000864. doi:10.12890/2018_000864 [PubMed 30756041]
  137. Vadas P. Hydrochlorothiazide-induced systemic capillary leak. Am J Emerg Med. 2020;38(6):1299.e1-1299.e2. doi:10.1016/j.ajem.2020.02.029 [PubMed 32139213]
  138. van Blijderveen JC, Straus SM, Rodenburg EM, et al. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med. 2014;127(8):763-771. doi:10.1016/j.amjmed.2014.04.014 [PubMed 24811554]
  139. van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics: current knowledge and future prospects. Paediatr Drugs. 2006;8(4):245-264. [PubMed 16898855]
  140. van Lieburg AF, Knoers NV, Monnens LA. Clinical Presentation and Follow-Up of 30 Patients With Congenital Nephrogenic Diabetes Insipidus. J Am Soc Nephrol. 1999;10(9):1958-1964. [PubMed 10477148]
  141. Vereda A, Cárdaba B, Quirce S, de las Heras M, Cuesta J, Sastre J. Immunological studies in a case of hydrochlorothiazide-induced pulmonary edema. J Investig Allergol Clin Immunol. 2005;15(4):297-298. [PubMed 16433212]
  142. Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol. 2018;14(suppl 2):60. doi:10.1186/s13223-018-0289-y [PubMed 30275849]
  143. Wermers RA, Kearns AE, Jenkins GD, Melton LJ. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med. 2007;120(10):911.e9-911.e9.11E15. doi:10.1016/j.amjmed.2006.07.044 [PubMed 17904464]
  144. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065 [PubMed 29133356]
  145. Wile D. Diuretics: a review. Ann Clin Biochem. 2012;49(Pt 5):419-431. doi:10.1258/acb.2011.011281 [PubMed 22783025]
  146. Wilson L, Nair KV, Saseen JJ. Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich). 2014;16(12):864-868. doi:10.1111/jch.12413 [PubMed 25258088]
  147. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
  148. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219. [PubMed 17555487]
  149. Zhang X, Zhao Q. Association of thiazide-type diuretics with glycemic changes in hypertensive patients: a systematic review and meta-analysis of randomized controlled clinical trials. J Clin Hypertens (Greenwich). 2016;18(4):342-351. doi:10.1111/jch.12679 [PubMed 26395424]
  150. Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. Diabetes Metab. 2009;35(6, pt 2):544-557. doi:10.1016/S1262-3636(09)73464-0 [PubMed 20152742]
Topic 8529 Version 733.0